Integral Health Asset Management LLC Makes New $13.40 Million Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Integral Health Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 420,000 shares of the company's stock, valued at approximately $13,402,000. Integral Health Asset Management LLC owned 0.34% of Apellis Pharmaceuticals at the end of the most recent quarter.

Several other large investors have also made changes to their positions in APLS. Boxer Capital Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $45,504,000. National Bank of Canada FI grew its holdings in Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock valued at $44,214,000 after purchasing an additional 1,385,080 shares during the period. Cibc World Markets Corp purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $41,014,000. Avoro Capital Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 10.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock worth $390,011,000 after buying an additional 1,111,111 shares during the period. Finally, Norges Bank purchased a new position in shares of Apellis Pharmaceuticals during the 4th quarter valued at approximately $34,662,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on APLS shares. Needham & Company LLC reduced their price objective on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Bank of America lowered shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the company from $41.00 to $23.00 in a research note on Friday, May 9th. Raymond James lowered Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and cut their price objective for the stock from $75.00 to $52.00 in a research note on Friday, May 9th. The Goldman Sachs Group decreased their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $40.42.

Apellis Pharmaceuticals Trading Down 2.0%

APLS traded down $0.34 during trading hours on Thursday, reaching $16.36. The company's stock had a trading volume of 2,545,604 shares, compared to its average volume of 2,229,767. The stock has a market cap of $2.06 billion, a PE ratio of -8.06 and a beta of 0.73. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.11 and a fifty-two week high of $43.99. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business's 50-day moving average is $20.66 and its 200-day moving average is $26.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business's revenue for the quarter was down 3.2% on a year-over-year basis. During the same period last year, the company earned ($0.54) EPS. As a group, equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel David O. Watson sold 5,569 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. This represents a 3.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).